Showing results (331-340 of 3,348) with videos related to
Sort By:
Pageof 335
Pharmacoeconomics|December 14, 2011
Incorporating calibrated model parameters into sensitivity analyses: deterministic and probabilistic approachesDouglas C A Taylor, Vivek Pawar, Denise T Kruzikas, et al.Pharmacoeconomics|May 8, 2012
Quetiapine: a pharmacoeconomic review of its use in bipolar disorderGreg L PloskerPharmacoeconomics|November 10, 2011
Does the EQ-5D reflect lost earnings?Carl Tilling, Marieke Krol, Aki Tsuchiya, et al.Pharmacoeconomics|August 16, 2011
Economic evaluation of policy options for prevention and control of cervical cancer in ThailandNaiyana Praditsitthikorn, Yot Teerawattananon, Sripen Tantivess, et al.Pharmacoeconomics|July 21, 2011
Cautions regarding the fitting and interpretation of survival curves: examples from NICE single technology appraisals of drugs for cancerMartin Connock, Chris Hyde, David MoorePharmacoeconomics|July 30, 2011
Does the market share of generic medicines influence the price level?: a European analysisPieter Dylst, Steven SimoensPharmacoeconomics|August 23, 2011
Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinomaAteesha F Mohamed, A Brett Hauber, Maureen P NearyPharmacoeconomics|August 23, 2011
Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisalGraham Scotland, Norman Waugh, Pamela Royle, et al.Pharmacoeconomics|March 14, 2012
Cost effectiveness of anticoagulation in acute coronary syndromesJaime Latour-Pérez, Eva de-Miguel-BalsaPharmacoeconomics|March 14, 2012
Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization programNadia Demarteau, Thomas Breuer, Baudouin StandaertPageof 335